43 results
8-K
EX-99.1
DYAI
Dyadic International Inc., DE
8 Nov 23
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
4:09pm
-effective messenger RNA (mRNA)
Ongoing preclinical animal studies showing positive results with high neutralizing antibody levels for seasonal and pandemic … Preclinical Animal Studies
C1 expressed adjuvanted ferritin nanoparticle H5N1 antigen targeting pandemic influenza (H5N1/Bird Flu) showed high
8-K
EX-10.1
DYAI
Dyadic International Inc., DE
19 Sep 23
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using DapibusTM
8:30am
by reason of acts of God, war, strikes, riots, storms, fires, earthquake, epidemic, pandemic, power shortage or failure, failure of the transportation system
8-K
EX-99.1
DYAI
Dyadic International Inc., DE
9 Aug 23
Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
4:08pm
Expanded collaboration with Phibro animal health/Abic Biological Laboratories
U.S. Patent granted for manufacturing seasonal and pandemic influenza … the functions of an anti-pandemic hub with a particular focus on the development and production of vaccines and monoclonal antibodies for the treatment
8-K
EX-99.1
9wg0 v9isnoj4
10 May 23
Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
4:35pm
8-K
EX-99.1
hyp8zlb3feeadcwa8fs2
29 Mar 23
Dyadic Reports 2022 Year End Results and Recent Company Progress
4:32pm
8-K
EX-99.1
a92jptdt6852v4
10 Nov 22
Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments
4:06pm
8-K
EX-10.1
aofwzy dy
11 May 22
Dyadic Announces Research, License and Collaboration for the Manufacture of
9:57am
8-K
f3soaqt9yh2f he
2 Dec 21
Other Events
8:30am